CLYM Climb Bio Inc.

Price (delayed)

$12.52

Market cap

$719.1M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.82

Enterprise value

$676.31M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 7

Eliem Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the ...

Highlights
CLYM's quick ratio has soared by 126% YoY and by 15% from the previous quarter
Climb Bio's equity has soared by 62% from the previous quarter and by 29% YoY
CLYM's debt has soared by 174% since the previous quarter and by 106% year-on-year
Climb Bio's EPS has plunged by 55% YoY and by 6% from the previous quarter

Key stats

What are the main financial stats of CLYM

CLYM stock price

How has the Climb Bio stock price performed over time
Intraday
-11.89%
1 week
-11.27%
1 month
-27.55%
1 year
456.44%
YTD
213%
QTD
-3.99%

Financial performance

How have Climb Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$64.76M
Net income
-$57.62M
Gross margin
N/A
Net margin
N/A
CLYM's net income is down by 23% year-on-year and by 9% since the previous quarter
The operating income has contracted by 15% YoY and by 8% from the previous quarter

Price vs fundamentals

How does CLYM's price correlate with its fundamentals

Growth

What is Climb Bio's growth rate over time

Valuation

What is Climb Bio stock price valuation
P/E
N/A
P/B
2.99
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Climb Bio's EPS has plunged by 55% YoY and by 6% from the previous quarter
The price to book (P/B) is 70% more than the last 4 quarters average of 2.0
Climb Bio's equity has soared by 62% from the previous quarter and by 29% YoY

Efficiency

How efficient is Climb Bio business performance
The company's return on equity fell by 38% YoY
The return on assets has declined by 37% year-on-year
CLYM's ROIC is down by 5% YoY and by 3% QoQ

Dividends

What is CLYM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLYM.

Financial health

How did Climb Bio financials performed over time
CLYM's quick ratio has soared by 126% YoY and by 15% from the previous quarter
The current ratio has soared by 123% YoY and by 13% from the previous quarter
CLYM's debt is 99% smaller than its equity
CLYM's debt has soared by 174% since the previous quarter and by 106% year-on-year
Climb Bio's equity has soared by 62% from the previous quarter and by 29% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.